The Third Intergroup Rhabdomyosarcoma Study
N = 1,062
- Population
- 1062 previously untreated eligible patients with rhabdomyosarcoma, entered after surgery
- Design
- Risk-based trial (1984 to 1991) in which 1062 previously untreated eligible patients were randomised or assigned to treatment by clinical group (I to IV), histology and primary site. Outcomes were compared between randomised groups and with IRS-II (1978 to 1984).
- Arms
- All patients entered on IRS-III (experimental, n = 1,062): Risk-based multiagent chemotherapy, with or without irradiation, by clinical group, histology and site
- People
- Crist W
Show the numbers
| Endpoint | Analysis | All patients entered on IRS-III | Control | Effect |
|---|---|---|---|---|
| PFSAll patients entered on IRS-III | finalCrist 1995 | 65% at 5 y | — | P<.001Printed as 65% +/- 2% in IRS-III versus 55% +/- 2% in IRS-II, P < .001 by stratified testing; the abstract does not say what the +/- value is. A comparison between successive studies, not a randomised comparison. |
| Endpoint | Analysis | All patients entered on IRS-III | Control | Effect |
|---|---|---|---|---|
| PFSAll patients entered on IRS-III | finalCrist 1995 | 65% at 5 y | — | P<.001Printed as 65% +/- 2% in IRS-III versus 55% +/- 2% in IRS-II, P < .001 by stratified testing; the abstract does not say what the +/- value is. A comparison between successive studies, not a randomised comparison. |